Journal article icon

Journal article

Sequelae and survivorship in patients treated with (131)I-MIBG therapy.

Abstract:

BACKGROUND: (131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. Newer treatment modalities are emerging for neuroendocrine tumours (NETs) and chromaffin cell tumours (CCTs), but many of these do not yet have adequate long-term follow-up to determine their longer term efficacy and sequelae. METHODS: Fifty-eight patients with metastatic NETs and CCTs who had received (131)I-MIBG therapy between 2000 and 2011 were analysed. Survival and any long-term haematolog...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/bjc.2013.365

Authors


Expand authors...
Journal:
British journal of cancer
Volume:
109
Issue:
3
Pages:
565-572
Publication date:
2013-08-05
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
URN:
uuid:70756033-c338-409f-898c-0514c97ae5ac
Source identifiers:
414746
Local pid:
pubs:414746

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP